| Added by | ircm doc |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer |
| Creator | Massa et al. |
| Author | Davide Massa |
| Author | Claudio Vernieri |
| Author | Lorenzo Nicolè |
| Author | Carmen Criscitiello |
| Author | Florence Boissière-Michot |
| Author | Séverine Guiu |
| Author | Gaia Griguolo |
| Author | Federica Miglietta |
| Author | Andrea Vingiani |
| Author | Riccardo Lobefaro |
| Author | Beatrice Taurelli Salimbeni |
| Author | Claudia Pinato |
| Author | Francesca Schiavi |
| Author | Silvia Brich |
| Author | Carlo Pescia |
| Author | Nicola Fusco |
| Author | Giancarlo Pruneri |
| Author | Matteo Fassan |
| Author | Giuseppe Curigliano |
| Author | Valentina Guarneri |
| Author | William Jacot |
| Author | Maria Vittoria Dieci |
| Abstract | BACKGROUND: The cutoff of <1% positive cells to define estrogen receptor (ER) negativity by immunohistochemistry (IHC) in breast cancer (BC) is debated. We explored the tumor immune microenvironment and gene-expression profile of patients with early-stage HER2-negative ER-low (ER 1%-9%) BC, comparing them to ER-negative (ER <1%) and ER-intermediate (ER 10%-50%) tumors. METHODS: Among 921 patients with early-stage I-III, ER ?50%, HER2-negative BCs, tumors were classified as ER-negative (n?=?712), ER-low (n?=?128), or ER-intermediate (n?=?81). Tumor-infiltrating lymphocytes (TILs) were evaluated. CD8+, FOXP3+ cells, and PD-L1 status were assessed by IHC and quantified by digital pathology. We analyzed 776 BC-related genes in 116 samples. All tests were 2-sided at a <.05 significance level. RESULTS: ER-low and ER-negative tumors exhibited similar median TILs, statistically significantly higher than ER-intermediate tumors. CD8/FOXP3 ratio and PD-L1 positivity rates were comparable between ER-low and ER-negative groups. These groups showed similar enrichment in basal-like intrinsic subtypes and comparable expression of immune-related genes. ER-low and ER-intermediate tumors showed significant transcriptomic differences. High TILs (?30%) were associated with improved relapse-free survival (RFS) in ER-low (5-year RFS 78.6% vs 66.2%, log-rank P?=?.033, hazard ratio [HR] 0.37 [95% CI = 0.15 to 0.96]) and ER-negative patients (5-year RFS 85.2% vs 69.8%, log-rank P? |
| Publication | Journal of the National Cancer Institute |
| Volume | 116 |
| Issue | 12 |
| Pages | 1914-1927 |
| Date | 2024-12-01 |
| Journal Abbr | J Natl Cancer Inst |
| Language | eng |
| DOI | 10.1093/jnci/djae178 |
| ISSN | 1460-2105 |
| Library Catalog | PubMed |
| Extra | PMID: 39083015 PMCID: PMC11630536 |
| Tags | Adult, Aged, B7-H1 Antigen, Biomarkers, Tumor, Breast Neoplasms, Female, Forkhead Transcription Factors, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry, Lymphocytes, Tumor-Infiltrating, Middle Aged, Neoplasm Staging, Prognosis, Receptor, ErbB-2, Receptors, Estrogen, Transcriptome, Tumor Microenvironment |
| Date Added | 2025/01/16 - 11:51:51 |
| Date Modified | 2025/01/16 - 11:51:51 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
